Articles from Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that an oral presentation and three posters, including one late breaker, highlighting the company’s respiratory syncytial virus (RSV) program, will be presented at the 13th International RSV Symposium (RSV 2025) being held March 12-15 at Bourbon Cataratas do Iguazu, in Iguazu Falls, Brazil.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal first quarter ended December 31, 2024.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2024 at 8:15 a.m. PT in San Francisco, CA.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the United States District Court of Massachusetts (“the Court”) has issued a ruling on a summary judgment motion filed by Pfizer, Inc. in connection with Enanta’s patent infringement lawsuit seeking damages for infringement of U.S. Patent No. 11,358,953 (“the ’953 Patent”) in the manufacture, use and sale of Pfizer’s COVID-19 antiviral, Paxlovid™ (nirmatrelvir tablets; ritonavir tablets).

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced positive topline results from the first-in-pediatrics Phase 2 study evaluating zelicapavir in hospitalized and non-hospitalized children aged 28 days to 36 months with respiratory syncytial virus (RSV). An antiviral effect was observed for the primary and secondary virology endpoints in the overall pooled efficacy population. The primary endpoint in Part 2 of the study, which focused on virology, showed a pronounced antiviral effect with a 1.4 log decline in viral load at Day 5 compared to placebo. Additionally, a rapid and robust virologic effect was observed in a prespecified subset of patients who were randomized within 3 days of symptom onset, with a 1.2 log decline in viral load at Day 5 compared to placebo. The study also showed that zelicapavir demonstrated a favorable safety profile and was well-tolerated in this pediatric population. Zelicapavir, which received Fast Track designation from the U.S. Food and Drug Administration (FDA), is a novel N-protein inhibitor in development as a once-daily oral treatment for RSV.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the company will hold a conference call and webcast on Monday, December 9 at 8:30 a.m. ET to share topline results from RSVPEDs, a first-in-pediatrics Phase 2 study evaluating zelicapavir in hospitalized and non-hospitalized children aged 28 days to 36 months with respiratory syncytial virus (RSV).

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal fourth quarter and year-ended September 30, 2024.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating best-in-class small molecule drugs for virology and immunology indications, today announced positive topline results from a Phase 2a human challenge study of EDP-323 in healthy adults infected with respiratory syncytial virus (RSV). These data demonstrated that EDP-323 was generally safe and well-tolerated and achieved an 85-87% reduction in viral load area under the curve (AUC) by qRT-PCR (p<0.0001), a 97-98% reduction in infectious viral load AUC by viral culture (p<0.0001), and a 66-78% reduction of total clinical symptoms score AUC (p<0.0001) compared to placebo. EDP-323, which received Fast Track designation from the U.S. Food and Drug Administration (FDA), is a novel L-protein inhibitor in development as a once-daily oral treatment for RSV.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that members of management will participate in three investor conferences being webcast in September:

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal third quarter ended June 30, 2024.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024 at 7:30 a.m. ET in New York, NY.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the JMP Securities Life Sciences Conference on May 14, 2024 at 10:00 a.m. ET in New York, NY.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal second quarter ended March 31, 2024.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that effective April 29, 2024, the Compensation Committee of Enanta Pharmaceuticals’ Board of Directors granted employment inducement awards to Matthew P. Kowalsky, Enanta’s new Chief Legal Officer, consisting of a non-qualified stock option to purchase 150,000 shares of its common stock, performance share units (PSUs) for 4,468 shares of its common stock, and relative total stockholder return units (rTSRUs) for 4,468 shares of its common stock, under the company’s 2024 Inducement Stock Incentive Plan.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the appointment of Matthew P. Kowalsky, J.D., as Chief Legal Officer. In this role, he will lead all legal and compliance activities for Enanta, as well as provide strategic guidance and corporate governance oversight.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2024, after the U.S. market closes on May 6, 2024. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta’s business, including its research and development pipeline.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that data from the company’s SPRINT (SARS-Cov-2 PRotease INhibitor Treatment) study of EDP-235 has been accepted for a poster presentation at ESCMID Global 2024 (formerly ECCMID) being held April 27–30 in Barcelona, Spain.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at Leerink Partners Global Biopharma Conference on March 13, 2024 at 10:40 a.m. ET in Miami, FL.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs in virology and immunology, today reported financial results for its fiscal first quarter ended December 31, 2023.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024 at 11:20 a.m. ET.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2023 after the U.S. market closes on February 7, 2024. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on the company’s business and research and development pipeline.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on indications in virology and immunology, today announced that Jay R. Luly, Ph.D., Enanta’s President and Chief Executive Officer, will provide an update across its pipeline and plans for 2024 during Enanta’s presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:45 a.m. PT.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:45 a.m. PT in San Francisco, CA.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at Evercore ISI HealthCONx Conference on November 29, 2023 at 7:55 a.m. ET in Miami, FL.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections, today reported financial results for its fiscal fourth quarter and year ended September 30, 2023.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial results for its fiscal fourth quarter and full year ended September 30, 2023 after the U.S. market closes on November 20, 2023. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on the company’s business and research and development pipeline.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced it will host a virtual key opinion leader event to discuss advances in the treatment landscape for RSV with global experts and highlight the company’s RSV pipeline.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced that data for EDP-323, its oral, once-daily, L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at the 9th European Scientific Working Group on Influenza (ESWI) Influenza Conference on September 17-20, 2023 at the Palacio de Congresos de Valencia in Valencia, Spain.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced that data for EDP-938, its oral, once-daily, N-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at IDWeek 2023 being held October 11 - 15, 2023 at the Boston Convention and Exhibition Center in Boston, MA.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that members of management will participate in four investor conferences being webcast in September and provide a business update:

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today reported financial results for its fiscal third quarter ended June 30, 2023.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial results for its fiscal third quarter ended June 30, 2023 after the U.S. market closes on August 7, 2023. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on the company’s business and research and development pipeline.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced positive topline data from a Phase 1 study assessing the safety, tolerability, and pharmacokinetics (PK) of orally administered single ascending doses (SAD) and multiple ascending doses (MAD) of EDP-323 in healthy adult subjects. EDP-323, which received Fast Track designation from the U.S. Food and Drug Administration (FDA), is a novel L-protein inhibitor in development as a once-daily oral treatment for respiratory syncytial virus (RSV). Data from the Phase 1 study demonstrated favorable safety, tolerability, and PK supportive of once-daily dosing, with good exposure multiples, thereby supporting further clinical advancement of EDP-323.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that preclinical data from Enanta’s out-licensing portfolio has been accepted for a poster presentation at the European Association for the Study of the Liver (EASL) International Liver Congress 2023 being held June 21 – 24, 2023 in Vienna, Austria at the Messe Wien Exhibition Congress Centre.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at Jefferies Global Healthcare Conference on June 7, 2023 at 12:30 p.m. ET in New York, NY.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two investor conferences being webcast in May:

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today reported financial results for its fiscal second quarter ended March 31, 2023.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced topline data from SPRINT (SARS-Cov-2 PRotease INhibitor Treatment), a double-blind, placebo-controlled Phase 2 clinical trial of EDP-235, Enanta’s oral, 3CL protease inhibitor, in non-hospitalized, symptomatic adults with mild or moderate COVID-19 who were not at high risk for severe disease.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2023 after the U.S. market closes on May 8, 2023. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta’s business, including its research and development pipeline.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced the sale to OMERS, one of Canada’s largest defined benefit pension plans, of 54.5% of Enanta’s future royalty payments from AbbVie Inc. on worldwide sales of MAVYRET®/MAVIRET®. The purchase price paid to Enanta was $200 million. OMERS right to receive royalty payments is based on net sales of the product beginning in July 2023 through June 2032, with total payments capped at 1.42 times the purchase price. Enanta retains 45.5% of all royalties until the cap is hit, at which point 100% of all further royalties revert to Enanta.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced the company will present two posters supporting the continued clinical development of EDP-235, its 3CL protease inhibitor in development as an oral, once-daily treatment for SARS-CoV-2 infection, and EDP-323, its L-protein inhibitor in development as an oral, once-daily treatment for respiratory syncytial virus (RSV), at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held April 15-18, 2023 both virtually and at the Bella Center Copenhagen in Copenhagen, Denmark.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EDP-323, Enanta’s L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV).

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that data for EDP-235, its lead 3CL protease inhibitor specifically designed as an oral, once-daily treatment for COVID-19, and EDP-323, its L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held April 15-18 both virtually and at the Bella Center Copenhagen in Copenhagen, Denmark.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced new data supporting the potential of EDP-235 for the treatment of COVID-19, which are being presented at the 36th International Conference on Antiviral Research (ICAR) being held March 13-17, 2023 at the Centre de Congrès de Lyon (Lyon Convention Center) in Lyon, France. The company will have one oral presentation and three poster presentations, showcasing the potential of EDP-235 and Enanta’s leadership in the development of small molecules for the treatment of viral respiratory infections.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that data for EDP-235, its lead 3CL protease inhibitor in development as an oral, once-daily treatment for COVID-19, will be presented at the 36th International Conference on Antiviral Research (ICAR) being held March 13-17, 2023 at the Centre De Congres De Lyon (Lyon Convention Center) in Lyon, France.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023 at 10:00 a.m. ET.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today reported financial results for its fiscal first quarter ended December 31, 2022.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023 at 8:40 a.m. ET.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2022 after the U.S. market closes on February 7, 2023. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta’s business, including its research and development pipeline.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., Enanta’s President and Chief Executive Officer, will provide an update across its pipeline of virology programs and plans for 2023 during Enanta’s presentation at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 3:00 p.m. PT.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023 at 3:00 p.m. PT.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two investor conferences being webcast in November:

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today reported financial results for its fiscal fourth quarter and year ended September 30, 2022.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial results for its fiscal fourth quarter and full year ended September 30, 2022 after the U.S. market closes on November 21, 2022. Enanta management will then host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta’s business, including its research and development pipeline.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced the initiation of SPRINT (SARS-Cov-2 PRotease INhibitor Treatment), a Phase 2 clinical trial of EDP-235, Enanta’s lead oral, 3CL protease inhibitor, in non-hospitalized, symptomatic adults with mild or moderate COVID-19. The study is designed to evaluate the safety, tolerability, and antiviral activity of 200mg and 400mg once-daily doses of EDP-235 compared to placebo.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced new preclinical data supporting the potential of EDP-235 for the treatment of COVID-19, which are being presented at IDWeek 2022 in Washington, DC.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it has dosed the first subject in its Phase 1 clinical trial of EDP-323, a novel, oral L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV).

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the initiation of a Phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of EDP-938, its novel N-protein inhibitor, in adults with acute respiratory syncytial virus (RSV) infection who are at high risk of complications, including the elderly and/or those with congestive heart failure, chronic obstructive pulmonary disease (COPD) or asthma.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced new preclinical data related to its RSV program, as well as new virology methods used for its RSV and hMPV programs, will be presented during the 12th International RSV Symposium at ICC Belfast in Northern Ireland, United Kingdom.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that new preclinical data related to its respiratory syncytial virus (RSV) program, as well as new virology methods used for its RSV and human metapneumovirus (hMPV) programs, will be presented at the 12th International RSV Symposium being held on September 29 – October 2, 2022 at the ICC Belfast in Northern Ireland, United Kingdom.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that new preclinical data for EDP-235, its lead oral coronavirus protease inhibitor specifically designed for the treatment of COVID-19, will be presented at IDWeek 2022 being held October 19 – 23, 2022 in Washington, DC.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two investor conferences being webcast in September:

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal third quarter ended June 30, 2022.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, today announced the appointment of Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer, effective today, August 8, 2022. With over 20 years of experience in drug development across a broad range of therapeutic areas, Dr. Rottinghaus will lead the development, regulatory, clinical and medical functions in support of Enanta’s pipeline.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal third quarter ended June 30, 2022 after the U.S. market closes on August 8, 2022. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta’s business, including its research and development pipeline.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, today announced positive topline data from a Phase 1 study assessing the safety, tolerability, and pharmacokinetics (PK) of orally administered single ascending doses (SAD) and multiple ascending doses (MAD) of EDP-235 in healthy adult subjects. EDP-235, a coronavirus 3CL protease inhibitor, which received Fast Track designation from the U.S. Food and Drug Administration (FDA), is specifically designed to be a once-daily, oral antiviral treatment for COVID-19. Data from the Phase 1 study demonstrated favorable safety, tolerability, and PK with strong exposure multiples over the EC90, thereby supporting the advancement of EDP-235 into a Phase 2 study using once-daily dosing, without ritonavir.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, announced today that it has filed suit in United States District Court for the District of Massachusetts against Pfizer, Inc. seeking damages for infringement of U.S. Patent No. 11,358,953 (the ’953 Patent) in the manufacture, use and sale of Pfizer’s COVID-19 antiviral, Paxlovid™ (nirmatrelvir tablets; ritonavir tablets). The United States Patent and Trademark Office awarded the patent to Enanta earlier this month based on Enanta’s July 2020 patent application describing coronavirus protease inhibitors invented by Enanta scientists. The complaint can be accessed on Enanta’s website here.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that data from Enanta’s internal development program portfolio for hepatitis B virus (HBV) and its out-licensing program portfolio for non-alcoholic steatohepatitis (NASH) have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) International Liver Congress 2022 being held June 22 – 26, 2022 in London, United Kingdom.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two fireside chats being webcast in June:

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported topline results for RSVP, its Phase 2b study evaluating EDP-938, a potent N-protein inhibitor, in otherwise healthy adults with community-acquired RSV. In this low-risk patient population which had mild, self-resolving upper respiratory tract infection, EDP-938 did not meet the primary endpoint of reduction in total symptom score compared to placebo, or the secondary antiviral endpoints. However, a statistically significant difference in the number of subjects achieving undetectable RSV RNA at the end of treatment at Day 5 was observed with EDP-938 compared to placebo (p=0.033). Further, EDP-938 demonstrated a favorable safety profile, consistent with that observed in approximately 500 subjects exposed to date. Enanta continues to evaluate EDP-938 in high-risk populations in ongoing and planned clinical studies, including pediatric patients, adult hematopoietic cell transplant recipients, and a high-risk adult population, all of which have the most significant unmet need.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal second quarter ended March 31, 2022.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2022 after the U.S. market closes on May 9, 2022. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta’s business, including its research and development pipeline.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EDP-235, its coronavirus 3CL protease inhibitor (also known as the main coronavirus protease, or Mpro) specifically designed as a once-daily, oral treatment for COVID-19.

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that data from its Phase 2 human challenge study has been published in The New England Journal of Medicine (NEJM).

Enanta Pharmaceuticals, Inc. (NASDAQENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it has dosed the first subject in its Phase 1 clinical trial of EDP-235, a coronavirus 3CL protease inhibitor (also known as the main coronavirus protease, or Mpro) specifically designed as a once-daily, oral treatment for COVID-19.